Profile: GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS)

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company’s product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas, such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Biddle Sawyer Limited is wholly owned subsidiary of the Company. During the year ended December 31, 2011, it launched Votrient and Revolade. Votrient is indicated for the treatment of renal cell carcinoma. Revolade is for the treatment of thrombocytopenia in adults with the blood disorder chronic immune thrombocytopenic purpura. The Company has two research and development (R&D) units, which include Chemistry Research & Development and Pharmaceutical Research & Development.